Showing results (411-420 of 457) with videos related to

Sort By:
Pageof 46
BMJ Open|March 25, 2019
Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's diseaseIvan Koychev, Jennifer Lawson, Tharani Chessell, et al.
BMJ Open|November 18, 2022
Understanding primary care diagnosis and management of sleep disturbance for people with dementia or mild cognitive impairment: a realist review protocolLeanne Greene, Aidin Aryankhesal, Molly Megson, et al.
The British Journal of Psychiatry : the Journal of Mental Science|December 22, 2012
Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trialRenee Romeo, Martin Knapp, Jennifer Hellier, et al.
Trials|December 6, 2017
PERFECTED enhanced recovery (PERFECT-ER) care versus standard acute care for patients admitted to acute settings with hip fracture identified as experiencing confusion: study protocol for a feasibility cluster randomized controlled trialSimon P Hammond, Jane L Cross, Lee Shepstone, et al.
Translational Psychiatry|October 24, 2019
Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer's diseaseByron Creese, Evangelos Vassos, Sverre Bergh, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigmsKrista L Lanctôt, Joan Amatniek, Sonia Ancoli-Israel, et al.
Lancet (London, England)|July 19, 2011
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trialSube Banerjee, Jennifer Hellier, Michael Dewey, et al.
International Psychogeriatrics|July 19, 2022
Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trialCatherine Henderson, Martin Knapp, Susan Stirling, et al.
Health Technology Assessment (Winchester, England)|November 6, 2023
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trialSube Banerjee, Nicolas Farina, Catherine Henderson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersHanna Huber, Wagner Scheeren Brum, Laia Montoliu-Gaya, et al.
Pageof 46